Changes in perceived health and functioning as a cost-effectiveness measure for olanzapine versus haloperidol treatment of schizophrenia Tunis S L, Johnstone B M, Gibson P J, Loosbrock D L, Dulisse B K Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Olanzapine in the treatment of schizophrenia. Type of intervention Treatment. Economic study type Cost-effectiveness analysis and cost-consequences analysis. Study population The study evaluated patients with schizophrenia and related psychotic disorders. Male and female outpatients over the age of 18 were included in this study. All patients met the DSMR-III-R criteria for schizophrenia, schizophrenic disorder and schizoaffective disorder. Patients had a minimum brief Psychiatric Rating Scale score of 18 and were intolerant to current antipsychotic therapy (excluding haloperidol). Exclusion criteria were not provided. Setting The setting was a hospital and the community. Dates to which data relate The effectiveness and resource use data were from a study published in 1997, and the unit costs were from 1995. Source of effectiveness data The effectiveness data were based on a single study, the details of which were published elsewhere. Link between effectiveness and cost data Both cost and effectiveness estimates were based on the same study sample. Resource and clinical data were collected prospectively. Study sample This study was based on a large multinational randomised controlled trial comparing the efficacy, safety and cost- effectiveness of olanzapine versus haloperidol in the treatment of schizophrenia. The sample size was not based on power calculations. A total of 1,996 patients were included in the trial, and were randomised in a 2:1 fashion to olanzapine or haloperidol. The evaluation of health outcomes for the economic analysis was based on the English- speaking subgroup of patients in the trial (UK, US and Canadian patients): 772 taking olanzapine and 383 taking haloperidol. The analysis of cost data included only the US patients: a sample of 812 patients. The patient inclusion NHS Economic Evaluation Database (NHS EED) Produced by the Centre for Reviews and Dissemination Copyright © 2019 University of York Page: 1 / 5